Safety outcomes from monarchE: Phase 3 study of abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER-2-, node-positive, high risk, early breast cancer

被引：0

作者：

Rugo, H. ^{[1
]}

O'Shaughnessy, J. ^{[2
]}

Song, C. ^{[3
]}

Broom, R. ^{[4
]}

Gumus, M. ^{[5
]}

Yamashita, T. ^{[6
]}

San Antonio, B. ^{[7
]}

Shahir, A. ^{[8
]}

Zimmermann, A. ^{[9
]}

Zagouri, F. ^{[10
]}

Reinisch, M. ^{[11
]}

机构：

[1] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA

[2] Baylor Univ, Med Ctr, Texas Oncol, Dallas, TX USA

[3] Fujian Med Univ Union, Fuzhou, Fujian, Peoples R China

[4] Auckland DHB Oncol, Auckland, New Zealand

[5] Arastirma Hastanesi, Istanbul, Turkey

[6] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan

[7] Eli Lilly & Co, Madrid, Spain

[8] Eli Lilly & Co, Basingstoke, Hants, England

[9] Eli Lilly & Co, Indianapolis, IN 46285 USA

[10] Gen Hosp Athens Alexandra, Athens, Greece

[11] Brustzentrum Kliniken, Essen, Germany

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P013

引用

页码：S23 / S24

页数：2